However, clinical translation of single-step RAF or MEK inhibition in cancer has been hampered by complex feedback mechanisms that are not only able to reactivate targeted pathways following treatment [18, 46], but also specifically and differentially operate in different tumor genetic backgrounds. The gene discussed is MAP2K7; the disease is cancer.